Duchenne News Tags: FDA

June 20, 2024

FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

Breaking news: US FDA has expanded approval of Sarepta Therapeutics’ gene therapy, Elevidys to Duchenne muscular dystrophy patients ages 4 and above. Elevidys has received traditional FDA approval for ambulatory...

FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy

Jett Foundation is thrilled to share that the U.S. Food and Drug Administration (FDA) has approved Duvyzat (givinostat) to treat children and adolescents with Duchenne muscular dystrophy (DMD). Please read...

Support Jett Foundation

Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Programs

Events